Prediction of relapse and survival in breast cancer patients by pS2 protein status.

Application of systemic adjuvant therapy for primary breast cancer patients requires a more accurate identification of patients at high risk for recurrence. We have quantitatively assessed the cytosolic levels of estrogen-regulated pS2 protein in tumors of 205 breast cancer patients (median follow-up, 47 mo). There were no significant associations between the level of pS2 protein and tumor size, lymph node status, and differentiation grade. Using length of relapse-free survival (RFS) and overall survival (OS) as end points, 11 ng of pS2 protein/mg of cytosol protein were found as the best cutoff level to discriminate between positive (pS2+) and negative (pS2-). Patients with pS2- tumors showed significantly shorter RFS and OS (P less than 0.0001) than patients with pS2+ tumors. Also after adjustment for tumor size, lymph node status, and estrogen receptor (ER) status, pS2 negativity was associated with earlier recurrence and death. Tumors positive for pS2 (55 of 205, 27%) were almost exclusively confined to the subclass of ER+ tumors (53 of 55, 96%). The death rate for patients with pS2+ tumors was one-tenth of the death rate for patients with pS2-/ER- tumors. In the patients with ER+ tumors, the prognostic power of the pS2 status was especially present in patients whose tumors were also positive for the progesterone receptor (5-yr RFS and OS, 85% and 97% for ER+/PgR+/pS2+ tumors compared with 50% and 54% for the patients with ER+/PgR+/pS2- tumors). In patients with axillary lymph node involvement (N+), pS2 status could discriminate strongly between a good and bad prognosis group (5-yr RFS and OS, 65% and 88% for N+/pS2+ compared with 32% and 34% for N+/pS2-). A similar phenomenon was observed in patients without axillary lymph node involvement (5-yr RFS and OS, 89% and 95% for N0/pS2+ compared with 58% and 82% for N0/pS2-). We conclude that the pS2 status of human primary breast tumors is an important variable for the identification of patients at high risk for recurrence and death. Knowledge of the cytosolic pS2 status appeared of particular importance to identify patients at high risk in the ER+/PgR+ subclass of tumors, and in both the N0 and N+ subclasses of patients.

[1]  J. Foekens,et al.  Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. , 1989, Cancer research.

[2]  J. Foekens,et al.  Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. , 1989, Cancer research.

[3]  I. Christensen,et al.  Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. , 1989, Cancer research.

[4]  G. Bonadonna,et al.  Cell kinetics as a prognostic indicator in node-negative breast cancer. , 1989, European journal of cancer & clinical oncology.

[5]  S. Hirohashi,et al.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.

[6]  G M Clark,et al.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. , 1989, The New England journal of medicine.

[7]  G. Bonadonna,et al.  Tumor grade as a prognostic factor in primary breast cancer. , 1989, European journal of cancer & clinical oncology.

[8]  J. Farndon,et al.  EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.

[9]  Osborne Ck,et al.  Adjuvant treatment of node-negative breast cancer. , 1989 .

[10]  D. Merkel,et al.  Adjuvant treatment of node-negative breast cancer. , 1989, Texas medicine.

[11]  DNA flow cytometry in the prognosis of node-negative breast cancer. , 1989, The New England journal of medicine.

[12]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[13]  R. Lathe,et al.  Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. , 1988, Science.

[14]  C. Redmond,et al.  Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Klijn,et al.  The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer , 1988, Cancer.

[16]  P Chambon,et al.  Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Chambon,et al.  Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. , 1987, Endocrinology.

[18]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.

[19]  L. Skoog,et al.  Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. , 1987, Anticancer research.

[20]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[21]  K. Horwitz,et al.  Progestin action and progesterone receptor structure in human breast cancer: a review. , 1985, Recent progress in hormone research.

[22]  P Chambon,et al.  Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. , 1984, Nucleic acids research.

[23]  W. McGuire,et al.  Progesterone receptors as a prognostic factor in Stage II breast cancer. , 1983, The New England journal of medicine.

[24]  P. Chambon,et al.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. , 1982, Nucleic acids research.

[25]  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. , 1980, European Journal of Cancer.

[26]  W. McGuire,et al.  Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1975, Science.

[27]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[28]  J. M. Bremner,et al.  Statistical Inference under Restrictions , 1973 .